NCT02394093View on ClinicalTrials.gov

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Pharmacology, Clinical
Interventions
DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One stick pack containing 500 mg acetylsalicylic acid dry powder

DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One tablet containing 500 mg acetylsalicylic acid

DRUG

Aspirin (Acetylsalicylic acid, BAYe4465)

One effervescent tablet containing 500 mg acetylsalicylic acid

Trial Locations (1)

07601

Hackensack

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02394093 - To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults. | Biotech Hunter | Biotech Hunter